| Budget Amount *help |
¥3,250,000 (Direct Cost: ¥2,500,000、Indirect Cost: ¥750,000)
Fiscal Year 2012: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2011: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
|
|---|
| Research Abstract |
From surgically resected lower gingival squamous cell carcinoma samples, CD31 and VEGFR2 were highly expressed in vascular endothelial cells, and VEGF-A was expressed in tumor cells. The combination treatment of HSP90 inhibitor and mTOR inhibitor significantly inhibited VEGF induced cell proliferation, tube formation of human umbilical vein endothelial cells (HUVEC) more than the single treatment of them. Gelatin zymography showed that the combination treatment inhibited the activation of MMP-2 induced by VEGF in HUVEC more than the single treatment of them. Immunohistochemical analysis of mice xenografted with SAS oral squamous cell carcinoma cells showed a significant reduction in CD31-positive tumor vasculature in HSP90 inhibitor and mTOR inhibitor-administrated mouse tumor sections compared with the single treatment of them. Furthermore, the combination treatment of them suppressed both VEGFR2 and MMP-2 expression compared with both the control and the single treatments.
|
